11 May 2021
SpeeDx Receives CARB-X Funding to Develop Rapid Point-of-Care Diagnostic
SpeeDx announced it has been awarded up to US $1.8 million from CARB-X to address the rising threat of drug-resistant bacteria. Funds...
27 April 2021
Microbix & SpeeDx Form Exclusive Collaboration
Microbix Biosystems Inc. (TSX: MBX. OTCQB: MBXBF, Microbix®), a life sciences innovator and exporter, and SpeeDx Pty. Ltd. announced a...
26 April 2021
SpeeDx Receives CE-IVD Mark for PlexPCR® SARS-CoV-2
SpeeDx Pty. Ltd. announced today it has received CE-IVD marking for its PlexPCR® SARS-CoV-2* assay – a two gene test for the...
18 March 2021
SpeeDx partner with Neogen Diagnostik for distribution in Turkey
SpeeDx have announced signing a new distribution partner, further extending customer access to market-leading SpeeDx ResistancePlus® and PlexPCR® tests. Neogen Diagnostik...
18 March 2021
ResistancePlus® tests validated for cobas z 480 Analyzer
Roche customers will now have even more opportunities to utilise ResistancePlus® tests to support clinically important treatment decisions. SpeeDx ResistancePlus®...
3 February 2021
Continued Syphilis Outbreak Warrants National Attention
Syphilis remains an important public health concern due to global case increases. In Australia, the largest syphilis outbreak ever recorded...
